Making earlier cancer detection a routine part of medical care

Updated 2022 guidance Total revenue Screening Precision Oncology COVID testing S&M G&A R&D Amortization CapEx Prior guidance $1,980 - 2,022M $1,350 -1,372M EXACT SCIENCES $580-590M $50 - 60M $870-890M $770 - 790M $425 445M ~$99M ~$200M November 3 update $2,025 - 2,042M $1,375 -1,382M Exact Sciences guidance provided November 3, 2022; Screening guidance includes $1,335-1,340M from Cologuard and $40-42M from Prevention Genetics; Cologuard revenue includes immaterial revenue from Biomatrica products and Oncoguard Liver $595-600M $55 - 60M $825 - 845M $740 - 760M $390 - 405M ~$97M ~$200M A at midpoint +$33M +$18M +$13M +$3M -$45M -$30M -$38M -$2M LO 5

View entire presentation